Conditions of the Eyes and Joints Associated with Inflammatory Bowel Disease

Inflammatory Bowel Disease: Translating basic science into clinical practice

Volumn , Issue , 2010, Pages 553-561

  Orchard, Timothy R ^a   Jewell, Derek P ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Analgesia key element in management; Anti TNF antibodies used in peripheral arthritis in IBD; Arthritis and bacterial antigens Salmonella, Escherichia coli, Yersinia, Klebsiella and Campylobacter; Conditions of eyes and joints associated with inflammatory bowel disease; IBD arthritis interaction of genetic and environmental factors; Radiographs of sacroiliac joints means of diagnosis

Indexed keywords

EID: 84865717883     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444318418.ch37     Document Type: Chapter

References (48)

1. Bywaters E, Ansell B. Arthritis associated with ulcerative colitis: a clinical and pathological study. Ann Rheum Dis 1958; 17: 169-83.
2. Edwards F, Truelove S. The course and prognosis of ulcerative colitis. III. Complications. Gut 1964; 5:1-15.
3. Wright V,Watkinson G. The arthritis of ulcerative colitis. Br Med J 1965; ii:670-5.
4. Greenstein A, Janowitz H, Sachar D. Extra-intestinal complications of Crohn's disease and ulcerative colitis. Medicine (Baltimore) 1976; 55(6):401-12.
5. Stein H, Volpin G, Shapira D, et al. Musculoskeletal manifestations of Crohn's disease. Bull Hosp Joint Dis 1993; 53(1):17-20.
6. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42(3):387-91.
7. van der Linden S, van der Heijde DM. Clinical and epidemiologic aspects of ankylosing spondylitis and spondyloarthropathies. Curr Opin Rheumatol 1996; 8(4):269-74.
8. Calin A. Ankylosing spondylitis. In Oxford Textbook of Rheumatology (ed. W Maddison, DA Isenberg, P Woo, DN Glass), Oxford: Oxford University Press, 1998, pp. 1058-70.
9. Dekker-Saeys B, Meuwissen S, VandenBerg-Loonen E, et al. Prevalence of peripheral arthritis, sacroiliitis and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann Rheum Dis 1978; 37:33-5.
10. Wright V,Watkinson G. Sacroiliitis and ulcerative colitis. Br Med J 1965; ii:675-80.
11. Orchard T, Holt H, Bradley L, et al. Prevalence of sacroiliitis in Crohn's disease and its correlation with clinical, radiologic and genotypic parameters. Gastroenterology 2002; 122(4):W1298.
12. Hollingsworth P, Cheah P,Dawkins R et al. Observer variation in grading sacroiliac radiographs in HLA-B27 positive individuals. J Rheumatol 1983; 10(2):247-54.
13. McEniff N, Eustace S, McCarthy C, et al. Asymptomatic sacroiliitis in inflammatory bowel disease. Assessment by computed tomography. Clin Imaging 1995; 19(4):258-62.
14. Agnew JE, Pocock DG, Jewell DP. Sacroiliac joint uptake ratios in inflammatory bowel disease: relationship to back pain and to activity of bowel disease. Br J Radiol 1982; 55:821.
15. Dougados M, Linden S, Juhlin R, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991; 34(10):1218-27.
16. Brown MA, Pile KD, Kennedy LG, et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 1996; 55(4):268-70.
17. Leirisalo-Repo M, Suoranta H. Ten year follow-up study of patients with Yersinia arthritis. Arthritis Rheum 1988; 31:533-7.
18. Calin A, Fries JF. An "experimental" epidemic of Reiter's syndrome revisited. Follow-up evidence on genetic and environmental factors. Ann Intern Med 1976; 84(5):564-6.
19. Thomson GT, DeRubeis DA, Hodge MA, et al. Post-Salmonella reactive arthritis: late clinical sequelae in a point source cohort. Am J Med 1995; 98(1):13-21.
20. Olivieri I, Salvarani C, Cantini F. Is Behcet's disease part of the spondyloarthritis complex? J Rheumatol 1997; 24(10): 1870-2.
21. Dekker-Saeys B, Meuwissen S, Berg-Loonen EVD, et al. Clinical characteristics and results of histocompatibitility typing (HLA B27) in 50 patientswith both ankylosing spondylitis and inflammatory bowel disease. Ann Rheum Dis 1978; 37:36-41.
22. Brewerton D, Caffery M, Nicholls A et al. HL-A27 and arthropathies associated with ulcerative colitis and psoriasis. Lancet 1974; i:956-8.
23. Mallas EG, Mackintosh P, Asquith P, Cooke WT. Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27). Gut 1976; 17(11):906-10.
24. Steer S, Jones H, Hibbert J et al., Low back pain, sacroiliitis and the relationship with HLA-B27 in Crohn's disease. J Rheumatol 2003; 30(3):518-22.
25. Steer S, JonesH,Hibbert J et al. defined sacroiliitis andHLA-B27 in Crohn's disease. Gut 1999; 44(Suppl 1):A41.
26. Peeters H, Vander Cruyssen B, Laukens D, et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann Rheum Dis 2004; 63(9):1131-4.
27. Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000; 118(2): 274-8.
28. Ebringer A. Ankylosing spondylitis is caused by Klebsiella. Evidence from immunogenetic, microbiologic and serologic studies. Rheum Dis Clin North Am 1992; 18(1):105-21.
29. Gaston J, Life P, Granfors K et al. Synovial T lymphocyte recognition of organisms that trigger reactive arthritis. Clin Exp Immunol 1989; 76:348-53.
30. Hermann E, Fleischer B, Mayet WJ, et al. Response of synovial fluid T cell clones to Yersinia enterocolitica antigens in patients with reactive Yersinia arthritis. Clin Exp Immunol 1989; 75(3):365-70.
31. Hermann E, Yu D, zumBuschenfelde K, Fleischer B. HLA-B27- restricted CD8 T cells derived from synovial fluids of patients Conditions of the Eyes and Joints in IBD 561 with reactive arthritis and ankylosing spondylitis. Lancet, 1993; 342:646-50.
32. Rath H, Herfath H, Ikeda J, et al. Normal luminal bacteria, especially bacteroides species, mediate chronic colitis, gastritis and arthritis in HLA-B27/human ß2 microglobulin transgenic rats. J Clin Invest 1996; 98(4):945-53.
33. Taurog JD, Richardson JA, Croft JT, et al. The germ-free state prevents development of gut and joint inflammation in HLA B27 transgenic rats. J Exp Med 1994; 180:2359-64.
34. Rath H, Schulta M, Grenther W, et al. Colitis, gastritis and antibacterial lymphocyte responses in HLA-B27 transgenic rats monoinnoculated with Bacteroides vulgatus or Escherichia coli. Gastroenterology 1997; 112(4):A1068.
35. Rath H, Ikeda J,Wilson K, Sartor R. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 1997; 112(4):A1068.
36. Orchard TR, Jewell DP. The importance of ileocaecal integrity in the arthritic complications of Crohn's disease. Inflamm Bowel Dis 1999; 5(2):92-7.
37. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye and joint detected by a monoclonal antibody. Gastroenterology 1994; 107(1):103-8.
38. Guslandi M. Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: fact or fiction? World J Gastroenterol 2006; 12(10):1509-10.
39. Conti F, Ceccarelli F, Marocchi E, et al. Switching TNFa antagonists in patientswith ankylosing spondylitis and psoriatic arthritis: an observational study over a five-year period. Ann Rheum Dis 2007; 66(10):1393-7.
40. Cherouvim EP, Zintzaras E, Boki KA et al. Infliximab therapy for patientswith active and refractory spondyloarthropathies at the dose of 3 mg/kg: a 20-month open treatment. J Clin Rheumatol 2004; 10(4):162-8.
41. Sieper J, Rudwaleit M, Braun J. Adalimumab for the treatment of ankylosing spondylitis. Expert Opin Pharmacother 2007; 8(6):831-8.
42. Braun J, Baraliakos X, Listing J et al., Differences in the incidence of flares or new onset of inflammatory bowel diseases in patientswith ankylosing spondylitis exposed to therapywith antitumor necrosis factor alpha agents. Arthritis Rheum 2007; 57(4): 639-47.
43. Van den Bosch F, Kruithof E, De Vos M, et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356(9244):1821-2.
44. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41(9):1552-63.
45. Orchard TR, Chua C, Cheng H, Jewell DP. Clinical features of erythema nodosum (EN) and uveitis assocaited with inflammatory bowel disease. Gastroenterology 2000; 118(4):755.
46. Das KM, VecchiM, Sakamaki S. A shared and unique epitope(s) on human colon, skin and biliary epithelium detected by amonoclonal antibody. Gastroenterology 1990; 98(2):464-9.
47. Orchard TR, Dhar A, Simmons JD, et al. Phenotype determining genes in the HLA region may determine the presence of uveitis and erythema nodosum (EN) in inflammatory bowel disease. Gastroenterology 2000; 118(4):A4832.
48. Siemanowski B, Regueiro M. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease. Curr Treat Options Gastroenterol 2007; 10(3):178-84.